# Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

> **NCT06858839** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 3853 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Maridebart Cafraglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06858839
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-12
- **Primary completion:** 2027-01-21
- **Final completion:** 2027-04-16
- **Target enrollment:** 3853 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06858839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06858839, "Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT06858839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*